<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-38X1XNSB</identifier><date>2023</date><creator>Janić, Miodrag</creator><creator>Koceva, Andrijana</creator><creator>Kravos Tramšek, Nika Aleksandra</creator><creator>Lunder, Mojca</creator><relation>documents/doc/3/URN_NBN_SI_doc-38X1XNSB_001.pdf</relation><relation>documents/doc/3/URN_NBN_SI_doc-38X1XNSB_001.txt</relation><format format_type="issue">5</format><format format_type="volume">74</format><format format_type="type">article</format><format format_type="extent">str. 353-361</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">177607171</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-38X1XNSB</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">agonist receptorjev GIP</subject><subject language_type_id="slv">agonist receptorjev GLP-1</subject><subject language_type_id="slv">debelost</subject><subject language_type_id="slv">sladkorna bolezen</subject><subject language_type_id="slv">tirzapatid</subject><title>Preboj v zdravljenju presnovnih bolezni</title><title>inovativna molekula tirzepatid</title><title>Breakthrough in the treatment of metabolic disorders</title><title>innovative molecule tirzepatide</title></Record>